This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Elevation of Atherogenic Lipoproteins Caused by Impaired Catabolism

Robert W. Mahley, MD, PhD; Karl H. Weisgraber, PhD; Thomas L. Innerarity, PhD; Stanley C. Rall, Jr, PhD

JAMA. 1991;265(1):78-83.

Abstract
Certain proteins (called apolipoproteins B and E) on the surface of lipoprotein particles are responsible for mediating the binding of cholesterol-rich particles to specific lipoprotein receptors on the surface of cells and represent a major pathway controlling blood cholesterol levels. Three important disorders of lipoprotein metabolism, which provide insights into the molecular mechanisms responsible for the elevation of specific atherogenic lipoproteins, are the following: (1) Type III hyperlipoproteinemia results from specific mutations in apolipoprotein E that prevent the normal binding of chylomicron remnants and very-lowdensity lipoprotein remnants to lipoprotein receptors. Patients with this disorder who have elevated levels of these remnant lipoproteins develop atherosclerosis. (2) Familial defective apolipoprotein B-100 results from a single amino acid substitution in apolipoprotein B that prevents low-density lipoprotein from binding normally to the low-density lipoprotein receptor and elevates plasma cholesterol levels. (3) Familial hypercholesterolemia, which results in elevated levels of plasma low-density lipoprotein and premature atherosclerosis, is caused by a variety of mutations in the low-density lipoprotein receptor that interfere with the normal binding of lipoproteins to this receptor. These observations not only provide insights into the mechanisms responsible for normal lipoprotein metabolism, but also highlight the potential role of specific lipoproteins in atherogenesis.

(JAMA. 1991;265:78-83)

Author Affiliations
From the Gladstone Foundation Laboratories for Cardiovascular Disease, Cardiovascular Research Institute (Drs Mahley, Weisgraber, Innerarity, and Rall), the Department of Pathology (Drs Mahley, Weisgraber, and Innerarity), and the Department of Medicine (Dr Mahley), University of California, San Francisco.

Footnotes
Reprint requests to Gladstone Foundation Laboratories, PO Box 40608, San Francisco, CA 94140 (Dr Mahley).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Severe Hypercholesterolemia, Impaired Fat Tolerance, and Advanced Atherosclerosis in Mice Lacking Both Low Density Lipoprotein Receptor-related Protein 5 and Apolipoprotein E
Magoori et al.
J. Biol. Chem. 2003;278:11331-11336.
ABSTRACT | FULL TEXT  

The Effects of Dietary n-3 Polyunsaturated Fatty Acids Delivered in Chylomicron Remnants on the Transcription of Genes Regulating Synthesis and Secretion of Very-Low-Density Lipoprotein by the Liver: Modulation by Cellular Oxidative State
Botham et al.
Exp. Biol. Med. 2003;228:143-151.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia
van Dam et al.
Heart 2002;88:234-238.
ABSTRACT | FULL TEXT  

Characterization of an Apolipoprotein E3 Variant (Arg 145 -> His) Associated with Mild Hypertriglyceridemia
Hidaka et al.
Annals of Clinical & Laboratory Science 2001;31:163-170.
ABSTRACT | FULL TEXT  

Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
Mahley and Ji
J. Lipid Res. 1999;40:1-16.
ABSTRACT | FULL TEXT  

The NH2-terminal Region of Apolipoprotein B Is Sufficient for Lipoprotein Association with Glycosaminoglycans
Goldberg et al.
J. Biol. Chem. 1998;273:35355-35361.
ABSTRACT | FULL TEXT  

Fluorometric determination of total retinyl esters in triglyceride-rich lipoproteins
Orth et al.
Clin. Chem. 1998;44:1459-1465.
ABSTRACT | FULL TEXT  

Dietary Guidelines for Healthy American Adults: A Statement for Health Professionals From the Nutrition Committee, American Heart Association
Krauss et al.
Circulation 1996;94:1795-1800.
FULL TEXT  

Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease: The Framingham Offspring Study
Wilson et al.
JAMA 1994;272:1666-1671.
ABSTRACT  

Genetic and Environmental Influences on Serum Lipid Levels in Twins
Heller et al.
NEJM 1993;328:1150-1156.
ABSTRACT | FULL TEXT  

Virus-mediated Transduction of Apolipoprotein E (ApoE)-Sendai Develops Lipoprotein Glomerulopathy in ApoE-deficient Mice
Ishigaki et al.
J. Biol. Chem. 2000;275:31269-31273.
ABSTRACT | FULL TEXT  

A Broad Role for the Zinc Finger Protein ZNF202 in Human Lipid Metabolism
Wagner et al.
J. Biol. Chem. 2000;275:15685-15690.
ABSTRACT | FULL TEXT